<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="inhibit">
            <roleset id="inhibit.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="the entity being inhibited by agent to get binding&#x0A;" />
                    <role n="2" descr="the action or property being inhibited&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>10mM EDTA can totally inhibit Binding that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>10mM EDTA is able to totally inhibit Binding that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>10mM EDTA is totally inhibiting Binding that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>10mM EDTA may have totally inhibited Binding that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Binding is concentration dependent and saturable and has been totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Binding is concentration dependent and saturable and is able to be totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Binding is concentration dependent and saturable and is observed to be totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Binding is concentration dependent and saturable and is totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Binding is concentration dependent and saturable and may be totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>CRP-cAMP can inhibit sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>CRP-cAMP has inhibited sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>CRP-cAMP has the ability to inhibit sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>CRP-cAMP inhibited sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>CRP-cAMP is able to inhibit sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>CRP-cAMP may have inhibited sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>CRP-cAMP will inhibit sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Coexpression of MAD-3 also has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Coexpression of MAD-3 also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Coexpression of MAD-3 has also inhibited functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Coexpression of MAD-3 may have also inhibited functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>For example, the phosphatase associated with another protein has been inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>For example, the phosphatase associated with another protein is inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>For example, the phosphatase associated with another protein may be inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>For example, the phosphatase associated with another protein may have been inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>For example, the phosphatase associated with another protein was inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>For example, the phosphatase associates with another protein and is thereby inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>For example, the phosphatase may have associated with another protein and thereby has been inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells has also been inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells is also inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells wil also be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW can inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW has inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW is able to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW is observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW may have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW will have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW will inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadX-dependent activation is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 is observed to be inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 was inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 will be inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex has inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex is able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex is observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex may inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex will have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex will inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity is able to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="56">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="57">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="58">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="59">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, are able to selectively inhibit late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="60">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, are observed to selectively inhibit late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="61">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, have selectively inhibited late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="62">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, selectively inhibited late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="63">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, will selectively inhibit late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="64">
                    <text>Moreover, Dam methylation has inhibited binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="65">
                    <text>Moreover, Dam methylation inhibited binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="66">
                    <text>Moreover, Dam methylation is able to inhibit binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="67">
                    <text>Moreover, Dam methylation is observed to inhibit binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>Moreover, Dam methylation may have inhibited binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>Moreover, Dam methylation will inhibit binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="EGRAM" no="70">
                    <text>NK-cell-mediated cytotoxicity has been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="71">
                    <text>NK-cell-mediated cytotoxicity is able to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>NK-cell-mediated cytotoxicity is inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>NK-cell-mediated cytotoxicity is observed to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>NK-cell-mediated cytotoxicity was inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>NK-cell-mediated cytotoxicity will be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognized major histocompatibility complex (MHC) class I peptides and inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognized major histocompatibility complex (MHC) class I peptides and may have inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>Nitric oxide (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>Nitric oxide (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>Nitric oxide (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>Nitric oxide (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>Nitric oxide (NO) inhibiting platelet function activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>Nitric oxide (NO) that has inhibited platelet function activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>Nitric oxide (NO) that inhibits platelet function activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms being inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms that were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, has specifically inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, is able to specifically inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, specifically inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, will specifically inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis are inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis has been inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis were about to be inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis were inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then protein synthesis will be inhibited by 50 mg/ml chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml chloramphenicol for inhibiting protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>The phosphatases function and localization will be inhibited if the phosphatase associates with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>The phosphatases function and localization would be inhibited if the phosphatase associated with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>This synthetic peptide binding to P can inhibit its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>This synthetic peptide binding to P is able to inhibit its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>This synthetic peptide binding to P is observed to inhibit its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>This synthetic peptide binding to P may have inhibited its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>This synthetic peptide binds to P and inhibits its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>This synthetic peptide bound to P and then inhibited its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>This synthetic peptide have bound to P and then inhibited its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and protein extracts from the transfected COS cells have inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and protein extracts from the transfected COS cells may have inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and both the C alpha and C beta isoforms of the PKA catalytic subunit are able to be inhibited by protein extracts from the transfected COS cells.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and both the C alpha and C beta isoforms of the PKA catalytic subunit are inhibited by protein extracts from the transfected COS cells.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and both the C alpha and C beta isoforms of the PKA catalytic subunit are observed to be inhibited by protein extracts from the transfected COS cells.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and both the C alpha and C beta isoforms of the PKA catalytic subunit have been inhibited by protein extracts from the transfected COS cells.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and both the C alpha and C beta isoforms of the PKA catalytic subunit were inhibited by protein extracts from the transfected COS cells.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and both the C alpha and C beta isoforms of the PKA catalytic subunit will be inhibited by protein extracts from the transfected COS cells.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and protein extracts from the transfected COS cells are able to inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and protein extracts from the transfected COS cells are observed to inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and protein extracts from the transfected COS cells can inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and protein extracts from the transfected COS cells inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>intermediate events leading to the formation of clathrin-coated pits are able to be inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>intermediate events leading to the formation of clathrin-coated pits are inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="122">
                    <text>intermediate events leading to the formation of clathrin-coated pits are observed to be inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>intermediate events leading to the formation of clathrin-coated pits have been inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>intermediate events leading to the formation of clathrin-coated pits were inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>intermediate events leading to the formation of clathrin-coated pits will be inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>late events of clathrin-coated vesicle formation are able to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>late events of clathrin-coated vesicle formation are inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>late events of clathrin-coated vesicle formation are observed to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>late events of clathrin-coated vesicle formation has been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>late events of clathrin-coated vesicle formation were inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>late events of clathrin-coated vesicle formation will be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>platelet function can be inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>platelet function has been inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>platelet function is able to be inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>platelet function is inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>platelet function is observed to be inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>platelet function may have been inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>platelet function were inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>platelet function will be inhibited by Nitric oxide (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>rolipram can inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>rolipram has inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>rolipram has the ability to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>rolipram inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>rolipram inhibits multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>rolipram is able to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>rolipram is observed to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>sigma (54)-dependent glnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>sigma (54)-dependent glnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>sigma (54)-dependent glnAp2 is strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="150">
                    <text>the proteasome inhibitors MG132 and lactacystin are able to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>the proteasome inhibitors MG132 and lactacystin can inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>the proteasome inhibitors MG132 and lactacystin have inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>the proteasome inhibitors MG132 and lactacystin have the ability to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>the proteasome inhibitors MG132 and lactacystin inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>the proteasome inhibitors MG132 and lactacystin inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>the proteasome inhibitors MG132 and lactacystin may have inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>Binding was concentration dependent and saturable and was totally inhibited with 10mM EDTA, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>For example, the phosphatase may associate with another protein and thereby be inhibited in its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 is inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EMBO" no="4">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, selectively inhibit late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EMBO" no="5">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, specifically inhibits intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EMBO" no="6">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml chloramphenicol to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="GREC" no="1">
                    <text>CRP-cAMP inhibits sigma (54)-dependent glnAp2 strongly, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="GREC" no="2">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells was also inhibited by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="GREC" no="3">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="GREC" no="4">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="GREC" no="5">
                    <text>Moreover, Dam methylation inhibits binding of Lrp/PapI near the GATC1028 site and alters binding of Lrp at the GATC1130 site.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognize major histocompatibility complex (MHC) class I peptides and inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>Nitric oxide (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms that are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>This synthetic peptide bound to P and inhibited its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and protein extracts from the transfected COS cells inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>10mM EDTA (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>10mM EDTA (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>10mM EDTA (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>10mM EDTA (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>10mM EDTA (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>10mM EDTA (NO) inhibiting Binding activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>10mM EDTA (NO) that has inhibited Binding activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>10mM EDTA (NO) that inhibits Binding activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Binding are able to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Binding are inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Binding are observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Binding can be inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Binding has been inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Binding has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Binding in transiently transfected Jurkat T-leukemia cells has also been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Binding in transiently transfected Jurkat T-leukemia cells is also inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Binding in transiently transfected Jurkat T-leukemia cells was also inhibited 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Binding in transiently transfected Jurkat T-leukemia cells wil also be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>Binding is able to be inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>Binding is able to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>Binding is inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>Binding is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>Binding is observed to be inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>Binding is observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>Binding may have been inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>Binding was inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>Binding were inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>Binding were inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>Binding will be inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>Binding will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>For example, P associated with This synthetic peptide has been inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>For example, P associated with This synthetic peptide is inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>For example, P associated with This synthetic peptide may be inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>For example, P associated with This synthetic peptide may have been inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>For example, P associated with This synthetic peptide was inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>For example, P associates with This synthetic peptide and is thereby inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>For example, P may associate with This synthetic peptide and thereby be inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>For example, P may have associated with This synthetic peptide and thereby has been inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>For example, glnAp2 promoter associated with the CRP-cAMP complex has been inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>For example, glnAp2 promoter associated with the CRP-cAMP complex is inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>For example, glnAp2 promoter associated with the CRP-cAMP complex may be inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>For example, glnAp2 promoter associated with the CRP-cAMP complex may have been inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>For example, glnAp2 promoter associated with the CRP-cAMP complex was inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>For example, glnAp2 promoter associates with the CRP-cAMP complex and is thereby inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>For example, glnAp2 promoter may associate with the CRP-cAMP complex and thereby be inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>For example, glnAp2 promoter may have associated with the CRP-cAMP complex and thereby has been inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>For example, the phosphatase associated with another protein has been inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>For example, the phosphatase associated with another protein is inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>For example, the phosphatase associated with another protein may be inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>For example, the phosphatase associated with another protein may have been inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>For example, the phosphatase associated with another protein was inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>For example, the phosphatase associates with another protein and is thereby inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>For example, the phosphatase may associate with another protein and thereby be inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>For example, the phosphatase may have associated with another protein and thereby has been inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are able to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are able to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are observed to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are observed to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells has also been inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells is also inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells was also inhibited coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells wil also be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and has been totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and has been totally inhibited with coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and is able to be totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and is able to be totally inhibited with coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and is observed to be totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and is observed to be totally inhibited with coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and is totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and is totally inhibited with coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and may be totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and may be totally inhibited with coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 may have been inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 may have been inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 was concentration dependent and saturable and was totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 was concentration dependent and saturable and was totally inhibited with coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 was inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 was inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>GadW (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>GadW (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>GadW (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>GadW (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>GadW (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>GadW (NO) inhibiting GadX-dependent activation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>GadW (NO) that has inhibited GadX-dependent activation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>GadW (NO) that inhibits GadX-dependent activation activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>GadW can totally inhibit GadX-dependent activation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>GadW is able to totally inhibit GadX-dependent activation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>GadW is totally inhibiting GadX-dependent activation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>GadW may have totally inhibited GadX-dependent activation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA can inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA has inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA inhibits Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA is able to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA is observed to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA may have inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA will have inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>GadX activates expression of gadA and gadBC at any pH, while 10mM EDTA will inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Binding has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Binding is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Binding is observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Binding will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>GadX activates expression of gadA and gadBC at any pH, while NK-cell-mediated cytotoxicity has been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>GadX activates expression of gadA and gadBC at any pH, while NK-cell-mediated cytotoxicity is inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>GadX activates expression of gadA and gadBC at any pH, while NK-cell-mediated cytotoxicity is observed to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>GadX activates expression of gadA and gadBC at any pH, while NK-cell-mediated cytotoxicity will be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide can inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide has inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide inhibits platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide is able to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide is observed to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide may have inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide will have inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Nitric oxide will inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 can inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 inhibits Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 is able to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 is observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 may have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 will have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 will inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies can inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies has inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies inhibits NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies is able to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies may have inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies will have inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>GadX activates expression of gadA and gadBC at any pH, while cell-surface receptors of the immunoglobulin and C-type lectin superfamilies will inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol can inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol has inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol inhibits protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol is able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol is observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol may have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol will have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol will inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 can inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 inhibits Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 is able to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 is observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 may have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 will have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 will inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>GadX activates expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicle formation has been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>GadX activates expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicle formation is inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>GadX activates expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicle formation is observed to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>GadX activates expression of gadA and gadBC at any pH, while late events of clathrin-coated vesicle formation will be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>GadX activates expression of gadA and gadBC at any pH, while platelet function has been inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>GadX activates expression of gadA and gadBC at any pH, while platelet function is inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>GadX activates expression of gadA and gadBC at any pH, while platelet function is observed to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>GadX activates expression of gadA and gadBC at any pH, while platelet function will be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin can inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin has inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin inhibits the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin is able to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin is observed to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin may have inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin will have inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin will inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>GadX activates expression of gadA and gadBC at any pH, while protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>GadX activates expression of gadA and gadBC at any pH, while protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>GadX activates expression of gadA and gadBC at any pH, while protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>GadX activates expression of gadA and gadBC at any pH, while protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex can inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex has inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex is able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex is observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex may have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex will have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex will inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I can inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I has inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I inhibits late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is able to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is observed to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I may have inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I will have inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I will inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the downregulation of phosphorylated Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the downregulation of phosphorylated Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the downregulation of phosphorylated Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>GadX-dependent activation are able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>GadX-dependent activation are inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>GadX-dependent activation are observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>GadX-dependent activation can be inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>GadX-dependent activation has been inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>GadX-dependent activation in transiently transfected Jurkat T-leukemia cells has also been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>GadX-dependent activation in transiently transfected Jurkat T-leukemia cells is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>GadX-dependent activation in transiently transfected Jurkat T-leukemia cells was also inhibited GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>GadX-dependent activation in transiently transfected Jurkat T-leukemia cells wil also be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>GadX-dependent activation is able to be inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>GadX-dependent activation is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>GadX-dependent activation is concentration dependent and saturable and has been totally inhibited with GadW, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>GadX-dependent activation is concentration dependent and saturable and is able to be totally inhibited with GadW, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>GadX-dependent activation is concentration dependent and saturable and is observed to be totally inhibited with GadW, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>GadX-dependent activation is concentration dependent and saturable and is totally inhibited with GadW, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>GadX-dependent activation is concentration dependent and saturable and may be totally inhibited with GadW, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>GadX-dependent activation is inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>GadX-dependent activation is observed to be inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>GadX-dependent activation is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>GadX-dependent activation may have been inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>GadX-dependent activation was concentration dependent and saturable and was totally inhibited with GadW, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>GadX-dependent activation was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>GadX-dependent activation were inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>GadX-dependent activation were inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>GadX-dependent activation will be inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Here, we have found that Binding has been inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Here, we have found that Binding is inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Here, we have found that Binding is observed to be inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Here, we have found that Binding was inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Here, we have found that Binding will be inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by the by coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by the coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by the by coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by the coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by the by coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by the coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 was inhibited by the by coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 was inhibited by the coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by the by coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by the coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Here, we have found that GadX-dependent activation has been inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Here, we have found that GadX-dependent activation is inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Here, we have found that GadX-dependent activation is observed to be inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Here, we have found that GadX-dependent activation was inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Here, we have found that GadX-dependent activation will be inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Here, we have found that NK-cell-mediated cytotoxicity has been inhibited by the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Here, we have found that NK-cell-mediated cytotoxicity is inhibited by the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Here, we have found that NK-cell-mediated cytotoxicity is observed to be inhibited by the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Here, we have found that NK-cell-mediated cytotoxicity was inhibited by the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Here, we have found that NK-cell-mediated cytotoxicity will be inhibited by the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Here, we have found that late events of clathrin-coated vesicle formation has been inhibited by the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Here, we have found that late events of clathrin-coated vesicle formation is inhibited by the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Here, we have found that late events of clathrin-coated vesicle formation is observed to be inhibited by the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Here, we have found that late events of clathrin-coated vesicle formation was inhibited by the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Here, we have found that late events of clathrin-coated vesicle formation will be inhibited by the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Here, we have found that platelet function has been inhibited by the Nitric oxide, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Here, we have found that platelet function is inhibited by the Nitric oxide, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Here, we have found that platelet function is observed to be inhibited by the Nitric oxide, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Here, we have found that platelet function was inhibited by the Nitric oxide, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Here, we have found that platelet function will be inhibited by the Nitric oxide, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Here, we have found that protein synthesis has been inhibited by the chloramphenicol, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Here, we have found that protein synthesis is inhibited by the chloramphenicol, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Here, we have found that protein synthesis is observed to be inhibited by the chloramphenicol, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Here, we have found that protein synthesis was inhibited by the chloramphenicol, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Here, we have found that protein synthesis will be inhibited by the chloramphenicol, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Here, we have found that the glnAp2 promoter activity has been inhibited by the the CRP-cAMP complex, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Here, we have found that the glnAp2 promoter activity is inhibited by the the CRP-cAMP complex, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Here, we have found that the glnAp2 promoter activity is observed to be inhibited by the the CRP-cAMP complex, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Here, we have found that the glnAp2 promoter activity was inhibited by the the CRP-cAMP complex, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Here, we have found that the glnAp2 promoter activity will be inhibited by the the CRP-cAMP complex, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA has inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA has the ability to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA inhibits Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA is able to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA is observed to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA may inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA will have inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that 10mM EDTA will inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Binding has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Binding is able to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Binding is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Binding is observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Binding will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is able to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW has inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is able to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW may inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW will have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW will inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-cell-mediated cytotoxicity has been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-cell-mediated cytotoxicity is able to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-cell-mediated cytotoxicity is inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-cell-mediated cytotoxicity is observed to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-cell-mediated cytotoxicity will be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide has inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide has the ability to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide inhibits platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide is able to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide is observed to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide may inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide will have inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Nitric oxide will inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 has the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 inhibits Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 is able to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 is observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 may inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 will have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 will inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies has inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies has the ability to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies inhibits NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies is able to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies may inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies will have inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies will inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol has inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol inhibits protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol is able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol is observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol may inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol will have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that chloramphenicol will inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 has the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 inhibits Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 is able to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 is observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 may inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 will have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that coexpression of MAD-3 will inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicle formation has been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicle formation is able to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicle formation is inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicle formation is observed to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicle formation will be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function has been inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function is able to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function is inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function is observed to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that platelet function will be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin has inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin has the ability to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin inhibits the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin is able to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin is observed to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin may inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin will have inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin will inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis is able to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I has inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I has the ability to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I inhibits late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is able to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is observed to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I may inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I will have inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I will inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the downregulation of phosphorylated Stat4, Stat5 and Stat6 is able to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the downregulation of phosphorylated Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the downregulation of phosphorylated Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the downregulation of phosphorylated Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>NK-cell-mediated cytotoxicity are able to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>NK-cell-mediated cytotoxicity are inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>NK-cell-mediated cytotoxicity are observed to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>NK-cell-mediated cytotoxicity can be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>NK-cell-mediated cytotoxicity has been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>NK-cell-mediated cytotoxicity in transiently transfected Jurkat T-leukemia cells has also been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>NK-cell-mediated cytotoxicity in transiently transfected Jurkat T-leukemia cells is also inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>NK-cell-mediated cytotoxicity in transiently transfected Jurkat T-leukemia cells was also inhibited cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>NK-cell-mediated cytotoxicity in transiently transfected Jurkat T-leukemia cells wil also be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>NK-cell-mediated cytotoxicity is able to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>NK-cell-mediated cytotoxicity is concentration dependent and saturable and has been totally inhibited with cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>NK-cell-mediated cytotoxicity is concentration dependent and saturable and is able to be totally inhibited with cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>NK-cell-mediated cytotoxicity is concentration dependent and saturable and is observed to be totally inhibited with cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>NK-cell-mediated cytotoxicity is concentration dependent and saturable and is totally inhibited with cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>NK-cell-mediated cytotoxicity is concentration dependent and saturable and may be totally inhibited with cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>NK-cell-mediated cytotoxicity is inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>NK-cell-mediated cytotoxicity is observed to be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>NK-cell-mediated cytotoxicity may have been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>NK-cell-mediated cytotoxicity was concentration dependent and saturable and was totally inhibited with cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>NK-cell-mediated cytotoxicity were inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>NK-cell-mediated cytotoxicity were inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>NK-cell-mediated cytotoxicity will be inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>Nitric oxide can totally inhibit platelet function that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>Nitric oxide is able to totally inhibit platelet function that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>Nitric oxide is totally inhibiting platelet function that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>Nitric oxide may have totally inhibited platelet function that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>P has been strongly inhibited by This synthetic peptide, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>P is observed to be strongly inhibited by This synthetic peptide, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>P is strongly inhibited by This synthetic peptide, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Binding are inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Binding has been inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Binding were about to be inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Binding were inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Binding will be inhibited by 50 mg/ml 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 are inhibited by 50 mg/ml by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 are inhibited by 50 mg/ml coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by 50 mg/ml by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by 50 mg/ml coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 were about to be inhibited by 50 mg/ml by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 were about to be inhibited by 50 mg/ml coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by 50 mg/ml by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by 50 mg/ml coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation are inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation has been inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation were about to be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation were inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation will be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-cell-mediated cytotoxicity are inhibited by 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-cell-mediated cytotoxicity has been inhibited by 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-cell-mediated cytotoxicity were about to be inhibited by 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-cell-mediated cytotoxicity were inhibited by 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-cell-mediated cytotoxicity will be inhibited by 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation are inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation has been inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation were about to be inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation were inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation will be inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function are inhibited by 50 mg/ml Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function has been inhibited by 50 mg/ml Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function were about to be inhibited by 50 mg/ml Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function were inhibited by 50 mg/ml Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then platelet function will be inhibited by 50 mg/ml Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the downregulation of phosphorylated Stat4, Stat5 and Stat6 are inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the downregulation of phosphorylated Stat4, Stat5 and Stat6 were about to be inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the downregulation of phosphorylated Stat4, Stat5 and Stat6 were inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the downregulation of phosphorylated Stat4, Stat5 and Stat6 will be inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity are inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity has been inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity were about to be inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity were inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then the glnAp2 promoter activity will be inhibited by 50 mg/ml the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml 10mM EDTA for inhibiting Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml 10mM EDTA to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml GadW for inhibiting GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml GadW to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml Nitric oxide for inhibiting platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml Nitric oxide to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml by coexpression of MAD-3 for inhibiting Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml by coexpression of MAD-3 to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies for inhibiting NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml coexpression of MAD-3 for inhibiting Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml coexpression of MAD-3 to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml proteasome inhibitors MG132 and lactacystin for inhibiting the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml proteasome inhibitors MG132 and lactacystin to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml the CRP-cAMP complex for inhibiting the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml the CRP-cAMP complex to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I for inhibiting late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>This synthetic peptide can inhibit P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>This synthetic peptide has inhibited P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>This synthetic peptide has the ability to inhibit P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>This synthetic peptide inhibited P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>This synthetic peptide inhibits P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>This synthetic peptide is able to inhibit P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>This synthetic peptide may have inhibited P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>This synthetic peptide will inhibit P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and CRP-cAMP have inhibited sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and CRP-cAMP may have inhibited sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and This synthetic peptide have inhibited P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and This synthetic peptide may have inhibited P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and another protein have inhibited the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and another protein may have inhibited the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and the CRP-cAMP complex have inhibited glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and the CRP-cAMP complex may have inhibited glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and CRP-cAMP are able to inhibit sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and CRP-cAMP are observed to inhibit sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and CRP-cAMP can inhibit sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and CRP-cAMP inhibit sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and P are able to be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and P are inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and P are observed to be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and P have been inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and P were inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and P will be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and This synthetic peptide are able to inhibit P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and This synthetic peptide are observed to inhibit P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and This synthetic peptide can inhibit P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and This synthetic peptide inhibit P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and another protein are able to inhibit the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and another protein are observed to inhibit the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and another protein can inhibit the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and another protein inhibit the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter are able to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter are inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter are observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter have been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter were inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 are able to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 are inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 have been inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 were inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the CRP-cAMP complex are able to inhibit glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the CRP-cAMP complex are observed to inhibit glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the CRP-cAMP complex can inhibit glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the CRP-cAMP complex inhibit glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the phosphatase are able to be inhibited by another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the phosphatase are inhibited by another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the phosphatase are observed to be inhibited by another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the phosphatase have been inhibited by another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the phosphatase were inhibited by another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and the phosphatase will be inhibited by another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and CRP-cAMP inhibited sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and This synthetic peptide inhibited P with equal efficacy.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and another protein inhibited the phosphatase with equal efficacy.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and the CRP-cAMP complex inhibited glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>another protein binding to the phosphatase can inhibit The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>another protein binding to the phosphatase can inhibit its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>another protein binding to the phosphatase is able to inhibit The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>another protein binding to the phosphatase is able to inhibit its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>another protein binding to the phosphatase is observed to inhibit The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>another protein binding to the phosphatase is observed to inhibit its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>another protein binding to the phosphatase may have inhibited The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>another protein binding to the phosphatase may have inhibited its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>another protein binds to the phosphatase and inhibits The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>another protein binds to the phosphatase and inhibits its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>another protein bound to the phosphatase and inhibited The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>another protein bound to the phosphatase and inhibited its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>another protein bound to the phosphatase and then inhibited The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>another protein bound to the phosphatase and then inhibited its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>another protein can inhibit the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>another protein has inhibited the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>another protein has the ability to inhibit the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>another protein have bound to the phosphatase and then inhibited The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>another protein have bound to the phosphatase and then inhibited its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>another protein inhibited the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>another protein inhibits the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>another protein is able to inhibit the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>another protein may have inhibited the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>another protein will inhibit the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>both the C alpha and C beta isoforms of the PKA catalytic subunit has been strongly inhibited by protein extracts from the transfected COS cells, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>both the C alpha and C beta isoforms of the PKA catalytic subunit is observed to be strongly inhibited by protein extracts from the transfected COS cells, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>both the C alpha and C beta isoforms of the PKA catalytic subunit is strongly inhibited by protein extracts from the transfected COS cells, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>by coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>by coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>by coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>by coexpression of MAD-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>by coexpression of MAD-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>by coexpression of MAD-3 (NO) inhibiting Functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>by coexpression of MAD-3 (NO) that has inhibited Functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>by coexpression of MAD-3 (NO) that inhibits Functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>by coexpression of MAD-3 can totally inhibit Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>by coexpression of MAD-3 is able to totally inhibit Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>by coexpression of MAD-3 is totally inhibiting Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>by coexpression of MAD-3 may have totally inhibited Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) inhibiting NK-cell-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) that has inhibited NK-cell-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies (NO) that inhibits NK-cell-mediated cytotoxicity activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies can totally inhibit NK-cell-mediated cytotoxicity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies is able to totally inhibit NK-cell-mediated cytotoxicity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies is totally inhibiting NK-cell-mediated cytotoxicity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>cell-surface receptors of the immunoglobulin and C-type lectin superfamilies may have totally inhibited NK-cell-mediated cytotoxicity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>chloramphenicol (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>chloramphenicol (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>chloramphenicol (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>chloramphenicol (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>chloramphenicol (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>chloramphenicol (NO) inhibiting protein synthesis activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>chloramphenicol (NO) that has inhibited protein synthesis activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>chloramphenicol (NO) that inhibits protein synthesis activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>chloramphenicol can totally inhibit protein synthesis that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>chloramphenicol is able to totally inhibit protein synthesis that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>chloramphenicol is totally inhibiting protein synthesis that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>chloramphenicol may have totally inhibited protein synthesis that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>coexpression of MAD-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>coexpression of MAD-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>coexpression of MAD-3 (NO) inhibiting Functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>coexpression of MAD-3 (NO) that has inhibited Functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>coexpression of MAD-3 (NO) that inhibits Functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>coexpression of MAD-3 can totally inhibit Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>coexpression of MAD-3 is able to totally inhibit Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>coexpression of MAD-3 is totally inhibiting Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>coexpression of MAD-3 may have totally inhibited Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>glnAp2 promoter has been strongly inhibited by the CRP-cAMP complex, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>glnAp2 promoter is observed to be strongly inhibited by the CRP-cAMP complex, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>glnAp2 promoter is strongly inhibited by the CRP-cAMP complex, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>its binding to C3b will be inhibited if P associates with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>its binding to C3b would be inhibited if P associated with This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>its function or localization will be inhibited if the phosphatase associates with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>its function or localization would be inhibited if the phosphatase associated with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>late events of clathrin-coated vesicle formation can be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>late events of clathrin-coated vesicle formation has been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>late events of clathrin-coated vesicle formation in transiently transfected Jurkat T-leukemia cells has also been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>late events of clathrin-coated vesicle formation in transiently transfected Jurkat T-leukemia cells is also inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>late events of clathrin-coated vesicle formation in transiently transfected Jurkat T-leukemia cells was also inhibited the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>late events of clathrin-coated vesicle formation in transiently transfected Jurkat T-leukemia cells wil also be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>late events of clathrin-coated vesicle formation is able to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>late events of clathrin-coated vesicle formation is able to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>late events of clathrin-coated vesicle formation is concentration dependent and saturable and has been totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>late events of clathrin-coated vesicle formation is concentration dependent and saturable and is able to be totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>late events of clathrin-coated vesicle formation is concentration dependent and saturable and is observed to be totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>late events of clathrin-coated vesicle formation is concentration dependent and saturable and is totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>late events of clathrin-coated vesicle formation is concentration dependent and saturable and may be totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>late events of clathrin-coated vesicle formation is inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>late events of clathrin-coated vesicle formation is inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>late events of clathrin-coated vesicle formation is observed to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>late events of clathrin-coated vesicle formation is observed to be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>late events of clathrin-coated vesicle formation may have been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>late events of clathrin-coated vesicle formation was concentration dependent and saturable and was totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>late events of clathrin-coated vesicle formation was inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>late events of clathrin-coated vesicle formation were inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>late events of clathrin-coated vesicle formation will be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>platelet function are able to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>platelet function are inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>platelet function are observed to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>platelet function has been inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>platelet function in transiently transfected Jurkat T-leukemia cells has also been inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>platelet function in transiently transfected Jurkat T-leukemia cells is also inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>platelet function in transiently transfected Jurkat T-leukemia cells was also inhibited Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>platelet function in transiently transfected Jurkat T-leukemia cells wil also be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>platelet function is able to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>platelet function is concentration dependent and saturable and has been totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>platelet function is concentration dependent and saturable and is able to be totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>platelet function is concentration dependent and saturable and is observed to be totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>platelet function is concentration dependent and saturable and is totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>platelet function is concentration dependent and saturable and may be totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>platelet function is inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>platelet function is observed to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>platelet function was concentration dependent and saturable and was totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>platelet function was inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>platelet function were inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>platelet function will be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) inhibiting the downregulation of phosphorylated Stat4, Stat5 and Stat6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) that has inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) that inhibits the downregulation of phosphorylated Stat4, Stat5 and Stat6 activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>proteasome inhibitors MG132 and lactacystin can totally inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>proteasome inhibitors MG132 and lactacystin is able to totally inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>proteasome inhibitors MG132 and lactacystin is totally inhibiting the downregulation of phosphorylated Stat4, Stat5 and Stat6 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>proteasome inhibitors MG132 and lactacystin may have totally inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>protein extracts from the transfected COS cells can inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>protein extracts from the transfected COS cells has inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>protein extracts from the transfected COS cells has the ability to inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>protein extracts from the transfected COS cells inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>protein extracts from the transfected COS cells inhibits both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>protein extracts from the transfected COS cells is able to inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>protein extracts from the transfected COS cells may have inhibited both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>protein extracts from the transfected COS cells will inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>protein synthesis are able to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>protein synthesis are inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>protein synthesis are observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>protein synthesis can be inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>protein synthesis has been inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>protein synthesis in transiently transfected Jurkat T-leukemia cells has also been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>protein synthesis in transiently transfected Jurkat T-leukemia cells is also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>protein synthesis in transiently transfected Jurkat T-leukemia cells was also inhibited chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>protein synthesis in transiently transfected Jurkat T-leukemia cells wil also be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>protein synthesis is able to be inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>protein synthesis is able to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>protein synthesis is concentration dependent and saturable and has been totally inhibited with chloramphenicol, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>protein synthesis is concentration dependent and saturable and is able to be totally inhibited with chloramphenicol, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>protein synthesis is concentration dependent and saturable and is observed to be totally inhibited with chloramphenicol, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>protein synthesis is concentration dependent and saturable and is totally inhibited with chloramphenicol, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>protein synthesis is concentration dependent and saturable and may be totally inhibited with chloramphenicol, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>protein synthesis is inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>protein synthesis is observed to be inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>protein synthesis may have been inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>protein synthesis was concentration dependent and saturable and was totally inhibited with chloramphenicol, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>protein synthesis was inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>protein synthesis were inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>protein synthesis were inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>protein synthesis will be inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>the 10mM EDTA are able to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>the 10mM EDTA can inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>the 10mM EDTA have inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>the 10mM EDTA have the ability to inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>the 10mM EDTA inhibit Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>the 10mM EDTA inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>the 10mM EDTA may have inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>the CRP-cAMP complex (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>the CRP-cAMP complex (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>the CRP-cAMP complex (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>the CRP-cAMP complex (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>the CRP-cAMP complex (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>the CRP-cAMP complex (NO) inhibiting the glnAp2 promoter activity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>the CRP-cAMP complex (NO) that has inhibited the glnAp2 promoter activity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>the CRP-cAMP complex (NO) that inhibits the glnAp2 promoter activity activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>the CRP-cAMP complex can inhibit glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>the CRP-cAMP complex can totally inhibit the glnAp2 promoter activity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>the CRP-cAMP complex has inhibited glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>the CRP-cAMP complex has the ability to inhibit glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>the CRP-cAMP complex inhibited glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>the CRP-cAMP complex inhibits glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>the CRP-cAMP complex is able to inhibit glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>the CRP-cAMP complex is able to totally inhibit the glnAp2 promoter activity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>the CRP-cAMP complex is totally inhibiting the glnAp2 promoter activity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>the CRP-cAMP complex may have inhibited glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>the CRP-cAMP complex may have totally inhibited the glnAp2 promoter activity that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>the CRP-cAMP complex will inhibit glnAp2 promoter strongly, by 21-fold.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>the GadW are able to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>the GadW can inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>the GadW have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>the GadW have the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>the GadW inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>the GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>the GadW may have inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>the Nitric oxide are able to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>the Nitric oxide can inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>the Nitric oxide have inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>the Nitric oxide have the ability to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>the Nitric oxide inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>the Nitric oxide inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>the Nitric oxide may have inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) inhibiting late events of clathrin-coated vesicle formation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) that has inhibited late events of clathrin-coated vesicle formation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) that inhibits late events of clathrin-coated vesicle formation activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I can totally inhibit late events of clathrin-coated vesicle formation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is able to totally inhibit late events of clathrin-coated vesicle formation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is totally inhibiting late events of clathrin-coated vesicle formation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I may have totally inhibited late events of clathrin-coated vesicle formation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>the by coexpression of MAD-3 are able to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>the by coexpression of MAD-3 can inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>the by coexpression of MAD-3 have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>the by coexpression of MAD-3 have the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>the by coexpression of MAD-3 inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>the by coexpression of MAD-3 inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>the by coexpression of MAD-3 may have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies are able to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies can inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies have inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies have the ability to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies may have inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>the chloramphenicol are able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>the chloramphenicol can inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>the chloramphenicol have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>the chloramphenicol have the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>the chloramphenicol inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>the chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>the chloramphenicol may have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>the coexpression of MAD-3 are able to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>the coexpression of MAD-3 can inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>the coexpression of MAD-3 have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>the coexpression of MAD-3 have the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>the coexpression of MAD-3 inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>the coexpression of MAD-3 inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>the coexpression of MAD-3 may have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 are able to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 are inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 are observed to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 can be inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 in transiently transfected Jurkat T-leukemia cells has also been inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 in transiently transfected Jurkat T-leukemia cells is also inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 in transiently transfected Jurkat T-leukemia cells was also inhibited proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 in transiently transfected Jurkat T-leukemia cells wil also be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is able to be inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is able to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and has been totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and is able to be totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and is observed to be totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and is totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and may be totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 may have been inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 was concentration dependent and saturable and was totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 were inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 were inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacystin (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 will be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>the glnAp2 promoter activity are able to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>the glnAp2 promoter activity are inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>the glnAp2 promoter activity are observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>the glnAp2 promoter activity can be inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>the glnAp2 promoter activity has been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>the glnAp2 promoter activity in transiently transfected Jurkat T-leukemia cells has also been inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>the glnAp2 promoter activity in transiently transfected Jurkat T-leukemia cells is also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>the glnAp2 promoter activity in transiently transfected Jurkat T-leukemia cells was also inhibited the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>the glnAp2 promoter activity in transiently transfected Jurkat T-leukemia cells wil also be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>the glnAp2 promoter activity is able to be inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>the glnAp2 promoter activity is able to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>the glnAp2 promoter activity is concentration dependent and saturable and has been totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>the glnAp2 promoter activity is concentration dependent and saturable and is able to be totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>the glnAp2 promoter activity is concentration dependent and saturable and is observed to be totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>the glnAp2 promoter activity is concentration dependent and saturable and is totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>the glnAp2 promoter activity is concentration dependent and saturable and may be totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>the glnAp2 promoter activity is inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>the glnAp2 promoter activity is inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>the glnAp2 promoter activity may have been inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>the glnAp2 promoter activity was concentration dependent and saturable and was totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>the glnAp2 promoter activity was inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>the glnAp2 promoter activity were inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>the glnAp2 promoter activity were inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>the glnAp2 promoter activity will be inhibited if glnAp2 promoter associates with the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>the glnAp2 promoter activity would be inhibited if glnAp2 promoter associated with the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>the phosphatase has been strongly inhibited by another protein, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>the phosphatase is observed to be strongly inhibited by another protein, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>the phosphatase is strongly inhibited by another protein, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>the the CRP-cAMP complex are able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>the the CRP-cAMP complex can inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>the the CRP-cAMP complex have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>the the CRP-cAMP complex have the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>the the CRP-cAMP complex inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>the the CRP-cAMP complex inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>the the CRP-cAMP complex may have inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I are able to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I can inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I have inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I have the ability to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I may have inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Dam methylation (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>Dam methylation (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>Dam methylation (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>Dam methylation (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>Dam methylation (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Dam methylation (NO) inhibiting binding of Lrp/PapI activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Dam methylation (NO) that has inhibited binding of Lrp/PapI activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Dam methylation (NO) that inhibits binding of Lrp/PapI activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Dam methylation can totally inhibit binding of Lrp/PapI that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Dam methylation is able to totally inhibit binding of Lrp/PapI that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Dam methylation is totally inhibiting binding of Lrp/PapI that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>Dam methylation may have totally inhibited binding of Lrp/PapI that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation can inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation has inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation inhibits binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation is able to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation is observed to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation may have inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation will have inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation will inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain can inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain has inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain inhibits intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain is able to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain is observed to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain may have inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain will have inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain will inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>GadX activates expression of gadA and gadBC at any pH, while binding of Lrp/PapI has been inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>GadX activates expression of gadA and gadBC at any pH, while binding of Lrp/PapI is inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>GadX activates expression of gadA and gadBC at any pH, while binding of Lrp/PapI is observed to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>GadX activates expression of gadA and gadBC at any pH, while binding of Lrp/PapI will be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>GadX activates expression of gadA and gadBC at any pH, while intermediate events leading to the formation of clathrin-coated pits has been inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>GadX activates expression of gadA and gadBC at any pH, while intermediate events leading to the formation of clathrin-coated pits is inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>GadX activates expression of gadA and gadBC at any pH, while intermediate events leading to the formation of clathrin-coated pits is observed to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>GadX activates expression of gadA and gadBC at any pH, while intermediate events leading to the formation of clathrin-coated pits will be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>Here, we have found that binding of Lrp/PapI has been inhibited by the Dam methylation, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>Here, we have found that binding of Lrp/PapI is inhibited by the Dam methylation, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>Here, we have found that binding of Lrp/PapI is observed to be inhibited by the Dam methylation, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>Here, we have found that binding of Lrp/PapI was inhibited by the Dam methylation, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>Here, we have found that binding of Lrp/PapI will be inhibited by the Dam methylation, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>Here, we have found that intermediate events leading to the formation of clathrin-coated pits has been inhibited by the The N-terminal SH3 domain, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>Here, we have found that intermediate events leading to the formation of clathrin-coated pits is inhibited by the The N-terminal SH3 domain, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 is not sensitive to these inhibitors.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>Here, we have found that intermediate events leading to the formation of clathrin-coated pits is observed to be inhibited by the The N-terminal SH3 domain, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>Here, we have found that intermediate events leading to the formation of clathrin-coated pits was inhibited by the The N-terminal SH3 domain, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>Here, we have found that intermediate events leading to the formation of clathrin-coated pits will be inhibited by the The N-terminal SH3 domain, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation has inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation has the ability to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation inhibits binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation is able to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation is observed to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation may inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation will have inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation will inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain has inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain has the ability to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain inhibits intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain is able to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain is observed to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain may inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain will have inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain will inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding of Lrp/PapI has been inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding of Lrp/PapI is able to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding of Lrp/PapI is inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding of Lrp/PapI is observed to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding of Lrp/PapI will be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events leading to the formation of clathrin-coated pits has been inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events leading to the formation of clathrin-coated pits is able to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events leading to the formation of clathrin-coated pits is inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events leading to the formation of clathrin-coated pits is observed to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events leading to the formation of clathrin-coated pits will be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>The N-terminal SH3 domain (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>The N-terminal SH3 domain (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>The N-terminal SH3 domain (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>The N-terminal SH3 domain (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>The N-terminal SH3 domain (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>The N-terminal SH3 domain (NO) inhibiting intermediate events leading to the formation of clathrin-coated pits activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>The N-terminal SH3 domain (NO) that has inhibited intermediate events leading to the formation of clathrin-coated pits activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>The N-terminal SH3 domain (NO) that inhibits intermediate events leading to the formation of clathrin-coated pits activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>The N-terminal SH3 domain can totally inhibit intermediate events leading to the formation of clathrin-coated pits that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>The N-terminal SH3 domain is able to totally inhibit intermediate events leading to the formation of clathrin-coated pits that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>The N-terminal SH3 domain is totally inhibiting intermediate events leading to the formation of clathrin-coated pits that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>The N-terminal SH3 domain may have totally inhibited intermediate events leading to the formation of clathrin-coated pits that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then binding of Lrp/PapI are inhibited by 50 mg/ml Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then binding of Lrp/PapI has been inhibited by 50 mg/ml Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then binding of Lrp/PapI were about to be inhibited by 50 mg/ml Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then binding of Lrp/PapI were inhibited by 50 mg/ml Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then binding of Lrp/PapI will be inhibited by 50 mg/ml Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events leading to the formation of clathrin-coated pits are inhibited by 50 mg/ml The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events leading to the formation of clathrin-coated pits has been inhibited by 50 mg/ml The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events leading to the formation of clathrin-coated pits were about to be inhibited by 50 mg/ml The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events leading to the formation of clathrin-coated pits were inhibited by 50 mg/ml The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events leading to the formation of clathrin-coated pits will be inhibited by 50 mg/ml The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml Dam methylation for inhibiting binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml Dam methylation to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml The N-terminal SH3 domain for inhibiting intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml The N-terminal SH3 domain to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and rolipram have inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and rolipram may have inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram have inhibited P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram may have inhibited P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms are able to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and rolipram are able to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and rolipram are observed to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and rolipram can inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and rolipram inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P are able to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P will be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram are able to inhibit P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram are observed to inhibit P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram can inhibit P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram inhibit P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and rolipram inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and rolipram inhibited P with equal efficacy.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>binding of Lrp/PapI are able to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>binding of Lrp/PapI are inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>binding of Lrp/PapI are observed to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>binding of Lrp/PapI can be inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>binding of Lrp/PapI has been inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>binding of Lrp/PapI has been inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>binding of Lrp/PapI in transiently transfected Jurkat T-leukemia cells has also been inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>binding of Lrp/PapI in transiently transfected Jurkat T-leukemia cells is also inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>binding of Lrp/PapI in transiently transfected Jurkat T-leukemia cells was also inhibited Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>binding of Lrp/PapI in transiently transfected Jurkat T-leukemia cells wil also be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>binding of Lrp/PapI is able to be inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>binding of Lrp/PapI is able to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>binding of Lrp/PapI is concentration dependent and saturable and has been totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>binding of Lrp/PapI is concentration dependent and saturable and is able to be totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>binding of Lrp/PapI is concentration dependent and saturable and is observed to be totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>binding of Lrp/PapI is concentration dependent and saturable and is totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>binding of Lrp/PapI is concentration dependent and saturable and may be totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>binding of Lrp/PapI is inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>binding of Lrp/PapI is inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>binding of Lrp/PapI is observed to be inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>binding of Lrp/PapI is observed to be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>binding of Lrp/PapI may have been inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>binding of Lrp/PapI was concentration dependent and saturable and was totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>binding of Lrp/PapI was inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>binding of Lrp/PapI were inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>binding of Lrp/PapI were inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>binding of Lrp/PapI will be inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>binding of Lrp/PapI will be inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>intermediate events leading to the formation of clathrin-coated pits are able to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>intermediate events leading to the formation of clathrin-coated pits are inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>intermediate events leading to the formation of clathrin-coated pits are observed to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>intermediate events leading to the formation of clathrin-coated pits can be inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>intermediate events leading to the formation of clathrin-coated pits has been inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>intermediate events leading to the formation of clathrin-coated pits has been inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>intermediate events leading to the formation of clathrin-coated pits in transiently transfected Jurkat T-leukemia cells has also been inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>intermediate events leading to the formation of clathrin-coated pits in transiently transfected Jurkat T-leukemia cells is also inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>intermediate events leading to the formation of clathrin-coated pits in transiently transfected Jurkat T-leukemia cells was also inhibited The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>intermediate events leading to the formation of clathrin-coated pits in transiently transfected Jurkat T-leukemia cells wil also be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>intermediate events leading to the formation of clathrin-coated pits is able to be inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>intermediate events leading to the formation of clathrin-coated pits is able to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>intermediate events leading to the formation of clathrin-coated pits is concentration dependent and saturable and has been totally inhibited with The N-terminal SH3 domain, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>intermediate events leading to the formation of clathrin-coated pits is concentration dependent and saturable and is able to be totally inhibited with The N-terminal SH3 domain, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>intermediate events leading to the formation of clathrin-coated pits is concentration dependent and saturable and is observed to be totally inhibited with The N-terminal SH3 domain, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>intermediate events leading to the formation of clathrin-coated pits is concentration dependent and saturable and is totally inhibited with The N-terminal SH3 domain, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>intermediate events leading to the formation of clathrin-coated pits is concentration dependent and saturable and may be totally inhibited with The N-terminal SH3 domain, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>intermediate events leading to the formation of clathrin-coated pits is inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>intermediate events leading to the formation of clathrin-coated pits is inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>intermediate events leading to the formation of clathrin-coated pits is observed to be inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>intermediate events leading to the formation of clathrin-coated pits is observed to be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>intermediate events leading to the formation of clathrin-coated pits may have been inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>intermediate events leading to the formation of clathrin-coated pits was concentration dependent and saturable and was totally inhibited with The N-terminal SH3 domain, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>intermediate events leading to the formation of clathrin-coated pits was inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>intermediate events leading to the formation of clathrin-coated pits were inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>intermediate events leading to the formation of clathrin-coated pits were inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>intermediate events leading to the formation of clathrin-coated pits will be inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>intermediate events leading to the formation of clathrin-coated pits will be inhibited by The N-terminal SH3 domain.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms is observed to be strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms is strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>rolipram can inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>rolipram has inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>rolipram has the ability to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>rolipram inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>rolipram inhibits multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>rolipram is able to inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>rolipram may have inhibited multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>rolipram will inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>the Dam methylation are able to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>the Dam methylation can inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>the Dam methylation have inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>the Dam methylation have the ability to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>the Dam methylation inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>the Dam methylation inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>the Dam methylation may have inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>the The N-terminal SH3 domain are able to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>the The N-terminal SH3 domain can inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>the The N-terminal SH3 domain have inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>the The N-terminal SH3 domain have the ability to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>the The N-terminal SH3 domain inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>the The N-terminal SH3 domain inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>the The N-terminal SH3 domain may have inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
